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ABSTRACT
Introduction. Glioblastoma is the most common, and the most lethal, primary malignant brain tumour in adults. The aim of 
the study was to present a comprehensive, data-based review of glioblastoma treatment research, considering all clinical trials 
and peer-reviewed journal publications.
Materials and methods. Data regarding all glioblastoma clinical trials that was available on 7 August 2019 on ClinicalTrials.gov 
was analysed. Information on interventions’ mechanisms of action was obtained from AdisInsight. A PubMed search for ‘gliob-
lastoma’ was performed in September 2019. Citation counts were gathered from Scopus. Custom software for obtaining and 
analyzing data was developed by the authors. 
Results. 1,388 clinical trials on glioblastoma with a start date between 1979 and 2020 were identified. The distribution of gliob-
lastoma clinical trial phases differs significantly from that of other high-mortality cancers. 526 unique interventions of clinical 
trials and 206 molecular targets have been isolated. 32,410 publications on glioblastoma have been found, the number having 
increased especially since 2006. Publications on identified treatment options comprised 32.2%. Publications on glioblastoma 
are cited on average 4.27 times per year. The average specificity of treatment options’ publications for glioblastoma is 6.9%.
Conclusions. Glioblastoma treatment options and their molecular targets can be quantitatively ranked according to their 
scientific research output. To the best of our knowledge, no such registries have been elaborated before.
Key words: glioblastoma, treatment, research, clinical trial, literature, review
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Introduction
Glioblastoma is the most common, and the most lethal, 
primary malignant brain tumour in adults. Each year, more 
than 3 per 100,000 people in the United States [1], Europe 
[2–4], Israel [5], Australia [6] and elsewhere are diagnosed 
with this WHO grade IV glioma, especially so in areas of 
higher socioeconomic status [7, 8]. Although there are re-
gions with a lower incidence, such as Japan, Korea [9, 10] and 
Jordan [11], the reason for this is not yet fully understood. 
The overall incidence is increasing [4, 9, 12], yet this has not 
been convincingly attributed either to growing mobile phone 
use [13, 14], nor to improved diagnostic techniques [15], nor 
merely to the ageing of society.
The tumour manifests itself predominantly in patients 
aged 55–85 [1], with a median age at diagnosis of 63 [12]. 
Incidence rates increase with age up to 80–85 years [12, 16]. 
WHO-recognised [17] risk factors include: risk increase after 
exposure to ionising radiation to the head and neck, and risk 
decrease with history of allergies and atopic disease [14]. 
Additionally, the diagnosis is not always straightforward and 
swift, as symptoms are often vague, including headache (27%), 
fatigue (20%), confusion (27%), and drowsiness (35%), before 
progressing to more neurologically distinctive ones such as 
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seizures (37%) and motor deficits (21%) [18]. Furthermore, 
the disease progresses quickly: Stensjøen et al. observed daily 
untreated tumour growth of 1.4% [19]. 
Consequently, the rapidly growing glioblastoma causes 
an enormous psycho-socioeconomic burden [20] to its often 
working-age and unsuspecting victims and their families.
The prognosis is highly unfavourable, with a five-year 
survival of no more than 5% [21]. This makes glioblastoma 
one of the most deadly cancers [22, 23]. Accordingly, survival 
is commonly given in months instead of years.
Palliative treatment (mostly with corticosteroids and anti-
convulsants) offers survival ranging from a few weeks to a few 
months [21]. Decades of research on surgical resection and 
radiotherapy have prolonged this to about 6–10 and 12 months 
respectively [21]. The 2005 introduction of concomitant and 
adjuvant temozolomide chemotherapy further increased sur-
vival by 2.5 months [24]. Refinement of these interventions 
has resulted in a current median survival of 16 months [25]. 
The remaining most frequently used treatment options include 
nitrosoureas (such as lomustine and carmustine), bevacizum-
ab [26] and tumour treating fields [27]. The outcomes are 
especially promising for the latter, with reports of expanding 
median overall survival to almost 21 months [28]. 
Despite these encouraging new treatment modalities 
emerging just since 2005, the results are far from satisfactory, 
given that there is an average of more than 20 years of life 
lost due to premature mortality caused by glioblastoma [29]. 
Further research is highly desirable.
Over time, scientific research has provided us with signif-
icant advances in our understanding of the histopathological 
characteristics of glioblastoma. In 1926, 62 years after Rudolf 
Virchow coined the term ‘glioma’, Percival Bailey and Harvey 
Cushing were able to distinguish ‘glioblastoma multiforme’ 
(GBM) as a separate entity, although the name acknowledged 
the variable gross appearance of the tumour [30]. Nowadays, 
glioblastoma is still classified as a high-grade glioma with 
predominant diffuse astrocytic differentiation exhibiting 
hypercellularity, nuclear atypia, mitotic activity with micro-
vascular proliferation and/or tumour necrosis [31]. Although 
the histopathology of the tumour remains extremely variable, 
with abundant cellular and nuclear polymorphisms alongside 
significant regional heterogeneity, the recent discoveries of 
molecular mechanisms and genetic alterations established the 
basis for the 2016 fourth edition of the WHO Classification of 
Tumours of the Central Nervous System [17] (Fig. S1, see sup-
plementary materials). This changed the way we perceive glio-
blastoma. The discoveries are so profound that after 90 years 
we now see a new shift in nomenclature. The popularity of the 
broad term ‘glioblastoma multiforme’ has waned, giving way 
to more specific entities such as IDH-wildtype glioblastoma, 
giant cell glioblastoma, gliosarcoma, epithelioid glioblastoma, 
IDH-mutant glioblastoma, etc. [32] (Fig. S2, see supplementa-
ry materials). Despite the limited therapeutic success, it would 
be unfair to say that glioblastoma treatment research is scarce. 
On the contrary: plentiful clinical trials are conducted [33–36] 
and articles published [37].
In fact, the amount of research is so abundant that it is 
challenging for any non-expert to grasp the glioblastoma 
therapeutic interventions outlook without becoming con-
fused [38]. The scientific community has recently recognised 
this problem, and summaries of past studies are beginning 
to emerge. In 2012, Nieder et al. [37] analysed patterns of 
citations and reviewed articles published on glioblastoma 
between 2006 and 2010. They showed glioblastoma research 
activity increasing over time. The Journal of Clinical Oncology 
and the Journal of Neuro-Oncology were the major scientific 
journals in the field. Among the top 10 cited articles, seven 
reported on genomic analyses, molecular subclasses or stem 
cells, with only two articles on phase II or III clinical trials. In 
2017, Cihoric et al. [34] analysed 2005–2015 phase II and III 
clinical trials, providing insight into, inter alia: experimental 
interventions, clinical trials’ funding, enrollment, and phase 
distribution. They found a high initiation of glioblastoma 
clinical trials, suggesting that this was caused by the failure 
of previous early investigative treatments to show satisfactory 
efficacy. The authors found that 51.9% of trials were funded 
primarily by the industry, consistent with other oncology 
clinical trials. They demonstrated, however, insufficient rep-
resentation of surgery, radiotherapy, and imaging focused 
trials, with these funded solely by academic institutions. At 
the time, the most researched topics were treatment options 
targeting EGFR or VEGF receptors and their pathways, as 
well as multi-TKIs. In 2018, Vanderbeek et al. [35] reviewed 
interventional glioblastoma clinical trials initiated between 
2005 and 2016, analysing, inter alia: clinical trials’ duration, 
enrollment, phase distribution, selected endpoints, and con-
nected publications as linked by ClinicalTrials.gov. The authors 
found that a significant minority of glioblastoma patients 
were enrolled in clinical trials, although this observation did 
not differ much from general oncology trials. They showed 
long development times to be characteristic of glioblastoma 
research, and suggested suboptimal decision making that 
led to too many patients with ineffective therapies engaging 
significant financial resources. Also in 2018, Paolillo et al. 
[33] reviewed 2015–2017 clinical trials and selected thera-
peutic strategies. They reported multiplying strategies against 
glioblastoma and a growing knowledge of genetic profiling 
and mutations. The authors considered new immunotherapy 
strategies to show the most promise. They stressed, however, 
that traditional therapies such as surgery, chemotherapy, and 
radiation remain the first line approaches to glioblastoma. 
In 2019, Zanders et al. [36] reviewed the 2016–2018 glio-
blastoma clinical trials. They concluded that small-molecule 
interventions have not significantly improved the standard of 
care, pointing out, nonetheless, that the vast majority of new 
clinical trials continue to focus on small-molecule therapy. 
They suggested however that together with smarter combi-
nation therapy selection and adaptive clinical trial design, 
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small-molecule interventions could still show success. These 
authors felt the best hope lay in novel immunotherapies and 
developments in the modulation of T cells.
The aim of the current study is to present a comprehensive, 
data-based review of glioblastoma treatment research, consid-
ering all past clinical trials and scientific journal publications. 
This article is intended to serve as a roadmap for anyone in-
terested in the subject, and as a guide for further research in 




Complete XML data for all clinical trials found by search-
ing for the condition of ‘glioblastoma’ was downloaded from 
ClinicalTrials.gov on 7 August 2019. Sought after information 
was extracted and saved: this included data on clinical trial 
status, phase, enrollment, intervention(s), study type, start, and 
completion dates. Calculations in the current study involved 
only clinical trials started after 1993, due to incomplete data 
for older entries.
Other cancers
Analogous information about clinical trials was gathered 
for cancers that had data on incidence, mortality, and five-year 
survival rate available on the National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER) Programme 
website [23]. The cancers selected are listed in Table S1 (see 
supplementary materials). This data was used to contrast and 
compare glioblastoma to other cancers.
Treatment options
Inclusion and exclusion criteria for interventions 
of glioblastoma clinical trials
Diagnostic interventions were intentionally excluded 
as they were not the subject of this study. Due to the au-
tomatic processing of large amounts of data, we included 
interventions with consistently identifiable nomenclature. 
Interventions with names that were not specific enough (e.g. 
‘surgery’, ‘radiation therapy’) were excluded. Interventions 
with synonymous names listed as separate entities on Clini-
calTrials.gov were merged. Combination interventions were 
divided into single entities. Interventions that were included 
in this study are summarised in Table S2 (see Supplementary 
materials).
Treatment options in scientific literature
We searched PubMed [39] for articles on the treatment of 
glioblastoma published from 2010 onwards. The search was 
conducted on 16 February 2019 with a query listed in Appen-
dix 1. Search results were imported to Mendeley Reference 
Management Software. Glioblastoma treatment options were 
extracted by reading through the titles and abstracts of the 
publications found.
Alternative names and categorisation
The National Cancer Institute Thesaurus [40] and Springer 
AdisInsight [41] were searched for synonyms of treatment 
options. A comprehensive list of alternative names (i.e. syno-
nyms) warranted the reliability of further automated literature 
analysis, and was therefore paid much attention.
AdisInsight [41] was also used for categorisation of treat-
ment options according to their ‘mechanism of action’ and 
(drug) ‘class’. We then combined the mechanisms of action 
into broader categories based on molecular targets of treatment 
options. The aim of this approach was to more clearly present 
numerous results.
Literature
PubMed [39] was selected as a source for data on glioblas-
toma research [42]. It was searched for each of the identified 
glioblastoma treatment options in September 2019. Search 
queries included previously gathered synonymous names. They 
were targeted to glioblastoma. The results were downloaded 
in XML format and parsed. Extracted information included 
publication identifiers (DOI, PMID), publication dates, jour-
nal, and publication type.
Accordingly, on 22 September 2019, the authors once 
again searched PubMed with queries for each of the identified 
treatment options. These queries were however targeted to 
neoplasms in general. They, too, included treatment options’ 
alternative names. Total number of publications found and 
their distribution by year were saved for each treatment option.
Finally, a large-scale PubMed search was performed for 
the entire field of glioblastoma research on 29 September 
2019 [39] to serve as a baseline for further analysis. Publication 
identifiers, dates, journals, affiliations, and types were saved.
All search queries used are listed in Appendix 1.
Glioblastoma specificity
Research specificity to glioblastoma was calculated for 
each treatment option as a percentage of publications on 
glioblastoma to all publications on neoplasms in general (as 
explained in the previous section).
Distribution of studies by country
Country information was extracted from the affiliations of 
glioblastoma publications gathered from PubMed. 
Citation analysis
Citation counts for all publications on glioblastoma (in-
cluding publications on identified glioblastoma treatment 
options) were gathered. Scopus [43] was selected as the most 
suitable source for citation data. This was primarily due to its 
advantageous coverage of newer (i.e. after 1995) publications 
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[42] that were deemed more valuable for the current study 
than older ones. In addition, the authors recognised Scopus’s 
advantage over Google Scholar and Web of Science in terms 
of website architecture and suitability for automated data 
collection. Given the large amount of data to gather (citation 
counts for over 30,000 publications), the process took six days.
Other cancers
Data on the number of publications on cancers selected 
from the SEER Programme website [23] (Tab. S1, see sup-
plementary materials), and their distribution by year, was 
downloaded from PubMed. 
Glioblastoma treatment research rating
The authors created an original algorithm for rating 
glioblastoma treatment options based on their research data. 
Treatment options were ordered by quantitative criteria and 
then ranked according to the sum of their relative positions 
in each criterion. These criteria consisted of: 1) the number 
of clinical trials conducted, 2) total enrollment, 3) average 
number of publications per year, 4) average citation count per 
publication per year, 5) specificity of publications to glioblas-
toma, and 6) year of introduction in a clinical trial, favouring 
newer treatments because past treatments have shown limited 
efficacy despite more time for fine-tuning the regimes. The 
items were ordered in descending order for all the criteria.
Mechanisms of action and their common molecular targets 
were selected in the same fashion, with an additional criterion 
of: 7) number of treatment options in each category, likewise 
in descending order.
Data gathering
All steps of data gathering were accompanied with C# .NET 
applications that saved the data in appropriate SQLite databas-
es. This tailor-made software was developed by the authors.
Statistical analysis
Basic descriptive analysis was carried out programming 
directly in SQL. The remaining descriptive, and all regression, 
analysis was performed in R programming language. The 
‘segmented’ R package [44] was used for change-point regres-
sion (Fig. S2, S5, S7, see supplementary materials). Obtaining 
p-values from confidence intervals was accomplished using 
the method proposed by Altman and Bland [45].
Results
Clinical trials
1,388 clinical trials on glioblastoma were identified, with 
start years ranging between 1979 and 2020. There has been 
a constant increase of almost four additional new trials started 
each year (R2 = 0.94, p < 0.001) since 1990 (Fig. S3, see supple-
mentary materials). This number now exceeds 90 yearly trials. 
The vast majority (91.6%) of clinical trials are of interventional 
study type, although there has been a slight decrease over time 
in favour of observational clinical trials (p < 0.01).
There are currently 379 (27.3%) active (recruiting, not 
recruiting or enrolling by invitation) clinical trials with com-
pletion dates after August 2019. Their enrollment totals 45,225. 
Early phase I (phase 0) trials comprise 16 (4.2%) trials, phase 
I — 168 (44.3%) trials, phase II — 164 (43.3%) trials, phase 
III — 23 (6.1%) trials, and phase IV — one (0.3%) trial. The 
distribution of phases in currently active clinical trials does not 
differ statistically significantly (p = 0.17) from the distribution 
of all-time interventional glioblastoma clinical trials (Fig. S4 B, 
see Supplementary materials). There is also no statistically sig-
nificant annual change in the relative distribution of glioblasto-
ma clinical trial phases. Nevertheless, each year, more clinical 
trial interventions are tested in phase I (increasing by 2.8 
per year, p < 0.001, R2 = 0.83) and phase II (increasing by 
3.0 per year, p < 0.001, R2 = 0.78) clinical trials. There seems 
to be also a moderate increase (by 0.3 per year, p < 0.05, 
R2 = 0.39) in interventions tested in phase IV trials (Fig. S4 C, 
see supplementary materials). No statistically significant in-
crease was found for phase III (p = 0.07, R2 = 0.18).
The distribution of glioblastoma clinical trial phases differs 
significantly from that of clinical trials for other examined 
high-mortality cancers (p < 0.001) (Fig. S4 A, see Supplemen-
tary materials). However, no statistically significant correlation 
between phase distribution and five-year survival or mortality 
rates was observed for the analysed 30 neoplasms.
Treatment options
1,583 unique entries for interventions of clinical trials have 
been identified. ClinicalTrials.gov categorises interventions 
into 11 categories (Tab. S2, see supplementary materials). 
‘Other’ interventions were largely composed of neuroradio-
logical (e.g. ‘MRI’), diagnostic (e.g. ‘blood draw’), and research 
(e.g. ‘questionnaire’). ‘Procedure’ category contained mostly 
surgical and diagnostic interventions. ‘Device’ interventions 
included many neurodiagnostic devices. ‘Genetic’ interven-
tions were almost exclusively laboratory techniques (e.g. ‘DNA 
analysis’, ‘polymorphism analysis’). ‘Behavioural’ category 
predominantly comprised activities such as ‘psychoeducation’ 
and ‘exercise’.
526 unique interventions of clinical trials have been 
isolated after data clean-up according to the procedure 
described in the Methods section. These interventions were 
undertaken 2,072 times in clinical trials. Each intervention 
was tested, on average, in 3.94 clinical trials (SD = 16.77). 
However, both the median and the mode are equal to 1, as 
more than half of the interventions were tested in single trials 
(278/526 = 52.8%).
Treatment options in scientific literature
1,487 publications were retrieved from the search on glio-
blastoma treatment. Investigation of the publications allowed 
for the identification of 181 treatment options. 172 of them 
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were listed as interventions in clinical trials. Not tested in 
clinical trials were nine treatment options (two nutritional and 
seven drugs). A total of 535 (526 + 9) glioblastoma treatment 
options further analysed in this study are summarised in Table 
S2 (see Supplementary materials).
Alternative names and categorisation
4,452 alternative names were identified for 515 (96.2%) 
treatment options, with an average of 8.64 names per treatment 
option (SD = 7.65). No synonyms were found for the remain-
ing 20 treatment options, mostly immunological (10/20, e.g. 
Ad-hCMV-TK) and radiotherapeutic (4/20).
427 mechanisms of action were found for 503 (94.0%) 
treatment options. There was an average of 2.34 mech-
anisms of action per treatment option (SD = 1.95), and 
2.75 treatment options per mechanism of action (SD = 5.04, 
median = 1). Molecular target-based categorisation allowed 
for a reduction of category number to 206. 407 (drug) 
classes were identified for 486 treatment options, with an 
average of 4.13 classes per treatment option (SD = 2.35), 
and 4.93 (SD = 21.8, median = 2) treatment options per 
class. Mechanisms of action and classes were unavailable 
in AdisInsight for radiotherapeutic and surgical treatment 
modalities as well as for therapeutic devices (e.g. Optune) 
and dietary supplements.
Novel treatment options
There have been, on average, 18 novel interventions intro-
duced annually in clinical trials (SD = 11, median = 18). This 
number increases each year by an average of 1.2 more novel 
treatment options, and currently exceeds 30 (Fig. 1). Every 
year, there are new mechanisms of action introduced as well 
as new common molecular targets. The latter, however, show 
a somewhat steadier annual rate (Fig. 1).
Figure 1. New treatment options, mechanisms of action, and molecular targets by year of first introduction in clinical trials
y = 1.20x–2390  R2 = 0.78 p < 0.001 
y = 0.64x–1264  R2 = 0.34 p < 0.001 
y = 0.16x–324  R2 = 0.08 p = 0.13 
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Literature
32,410 publications on glioblastoma have been identified. 
The number of publications is increasing each year and has 
especially accelerated since 2006 (Fig. S5 A, see supplementary 
materials). A summary of the most popular publication types 
is presented in Table S3 (see supplementary materials). Most 
papers on glioblastoma have been published in the journals 
listed in Table S4 (see supplementary materials). Similarly to 
that shown by Nieder et. al in 2012 [37], both the Journal of 
Clinical Oncology and the Journal of Neuro-Oncology con-
tinue to contain the highest numbers of glioblastoma articles. 
The latter, however, is approached by PloS one, Oncotarget and 
Cancer research (see Table S4 in supplementary materials).
10,435 publications on treatment options were found. This 
number increases each year and has especially accelerated 
since 2004. Publications on identified treatment options com-
prise 32.2% of all glioblastoma research. This percentage has 
increased statistically significantly (p < 0.001) since 1961 at an 
average yearly rate of 0.69% (Fig. S6, see supplementary mate-
rials). No publications were found for 129 treatment options. 
Each of the remaining 406 treatment options was presented in 
an average of 39 publications, although the median was equal 
to 7, mode to 1, and standard deviation was 196 publications. 
Treatment options are mentioned in publications targeted to 
glioblastoma, on average, 14.2 years (SD = 14.6 years, median 
= 8 years) after they were first mentioned in publications 
targeted to neoplasms in general. However, there seems to 
be a tendency towards shortening this timespan over time, 
especially after 1980, at an average rate of 0.29 years difference 
per year (p < 0.001) (Fig. S7, see supplementary materials).
Publication preceded clinical trial in the case of 200 treat-
ment options (on average by 10.9 years, SD = 10.8, median 
= 7 years). In 161 cases, publications appeared after the first 
clinical trial started (on average after 3.7 years, SD = 3.2, me-
dian = 3 years). In 32 cases, the first clinical trial started in the 
same year as the first publication (Fig. S8, see supplementary 
materials). There is no statistically significant change over time 
of the overall average timespan between the first clinical trial 
and the first publication (p = 0.61). There seems to be, however, 
a tendency to shorten this timespan in the clinical-trial-first 
group by an average of 0.2 years per year (R2 = 0.14, p < 0.001).
Glioblastoma specificity
Average specificity of publications on treatment options 
for glioblastoma is 6.9% (SD = 16.0%, median = 1.5%). There 
is no statistically significant trend for change over time when 
treatment options are analysed according to their clinical trial 
introduction year (p = 0.88, R2 < 0.01).
Distribution of studies by country
A world map with the numbers of cumulative glioblastoma 
articles (co)authored in given countries is presented in Fig. 
S9 (see supplementary materials). Over 81% of all glioblastoma 
articles have been published in just 11% of countries (n = 16). 
Moreover, articles from just seven countries (USA, China, 
Germany, Japan, Italy, France, and Canada) represent over 
53% of all the glioblastoma articles available on PubMed. The 
percentage shares of articles on the analysed treatment options 
relative to all glioblastoma articles remain fairly constant across 
countries: they are approximately normally distributed with 
a mean of 34% (SD = 5%).
An up-to-date world map showing the numbers of glio-
blastoma clinical trials is available online at https://clinical-
trials.gov/ct2/results/map?cond=Glioblastoma
Citation analysis
Citation data was available in Scopus for 30,267 publica-
tions on glioblastoma (94%). There is an average of 4.27 cita-
tions per publication per year (SD = 11.85, median = 2.08).
9,855 publications on treatment options for glioblastoma 
(94,4%) had citation data available in the Scopus database. 
There are statistically significantly (p < 0.05) more citations 
per publication per year in the publications on the treatment 
options group than in all publications on the glioblastoma 
group, an average for the former being 4.73 (SD = 12.04) with 
a median of 2.50 citations.
Changes over time of citations per publication per year 
of publications on glioblastoma and on treatment options in 
glioblastoma are presented in Figure 2.
It is possible that publications on glioblastoma generally 
favour the growth of journals’ impact factor, as the overall 
yearly citation effect is approaching its impact factor multi-
plied by 1.5 [46] (Tab. S4). However, a separate study would 
be needed for conclusive results. Factors to be taken into 
account should include, at least, publication type (article/ 
/review), yearly citations separated since publication, and 
yearly journal impact factor.
Of the top 10 articles with the most citations per year 
(Tab. S5, see supplementary materials), the majority report on 
glioblastoma characteristics rather than treatment, similarly to 
how it was described by Nieder et al. in their 2012 review [37].
Glioblastoma treatment research rating
The top 30 treatment options selected according to the pro-
posed algorithm are presented in Table 1. Molecular targets of the 
most researched treatment options are summarised in Table 2.
Limitations
Despite great attention to detail, planning and organi-
sation, the authors were unable to eliminate all limitations.
Clinical trials
The authors’ aspiration not to omit treatment options by 
limiting the study to subjective selection has, at times, led 
to overinclusion and posed a threat of overestimation. For 
example, the clinical trial NCT04028479 investigating chi-
meric antigen receptor T-cell therapy in 76 cancers (including 
glioblastoma) must have been manually excluded from the 
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Figure 2. Average citations of publications on glioblastoma and on glioblastoma treatment options
calculations of total enrollment due to the outlined value (en-
rollment of 100,000 when there is a total enrollment for all the 
remaining glioblastoma trials of 104,752). But not including 
this trial altogether because it is not glioblastoma-specific (as 
practiced by some authors) would however in itself induce bias 
by underestimating CAR-T research in glioblastoma. Although 
great attention was given to identifying and correcting any 
instances of such bias, some may have escaped our scrutiny.
Alternative names and categorisation  
of interventions
There is no one ideal way to categorise treatment options 
according to their mechanisms of action. The approach of 
presenting them in narrow categories, such as listed in the 
AdisInsight database, risks underestimation. For example, 
drugs targeting topoisomerase enzymes are listed under 
separate categories of type I and type II inhibitors. When the 
number of drugs is calculated independently for each category, 
topoisomerase is the 27th most numerous treatment target. 
When, however, both mechanisms of action are regarded as 
one category of topoisomerase-targeting drugs, topoisomerase 
becomes the 16th most numerous target. The authors believe 
the latter approach more faithfully represents the whole picture 
of glioblastoma treatment research, but we nonetheless must 
warn the reader of the risk of overestimation.
Epidemiological statistics
Readers should be warned that Table S2 (see supplementary 
materials) may be biased since, due to the limited epidemio-
logical data availability, a rather specific entity of glioblastoma 
is compared to broader disease definitions like breast or lung 
cancer (instead of e.g. small-cell lung cancer). However, the 
observation that there are more clinical trials on brain cancers 
than would be expected from the disease incidence is consist-
ent with the results of Hirsch et al. [47]. Our intention was to 
illustrate the noninferiority of glioblastoma research compared 
to other neoplasms, and also the ones of higher incidence.
Distribution of studies by country
Data for the analysis was gathered by means of a PubMed 
search, as explained in the Methods section. This may under-
state the number of articles from countries other than the USA 
and/or not written in English, as there is research published in 
local scientific journals not (fully) indexed on PubMed [48].
Conclusions
Glioblastoma treatment options can be quantitatively 
ranked according to their scientific research output, as pre-
sented in Table 1. Similarly, molecular targets can be ordered 
(Tab. 2). To the best of our knowledge, no such registries have 
been elaborated before. 
Additionally, to the best of our knowledge, this study is 
the first to have conducted an essential bibliometric analysis 
on all PubMed-found glioblastoma-related publications. 
Publications on glioblastoma are expected to be cited on 
average 4.27 times per year. Publications regarding treatment 
options are expected to be cited slightly more often (on av-
erage 4.73 times per year). Although further research would 
be desirable, these results suggest that journals may welcome 
publications on glioblastoma not only for their readability, but 
also for their citation advantage.
276


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Aleksander E. Łaba, Piotr Ziółkowski, Trends in glioblastoma treatment research
Scientists’ interest in publishing on glioblastoma has been 
increasing significantly since 2006, possibly due to the encour-
aging 2005 introduction of the Stupp protocol of temozolo-
mide treatment [24] (Fig. S5 A, see supplementary materials). 
It is interesting to note, however, that clinical trials have not 
followed that trend, with a rather steady annual increase rate 
(Fig. S3, see supplementary materials).
Nonetheless, the number of clinical trials on glioblastoma 
is constantly growing at a relative increase rate not inferior 
to that of other cancers. The best predictor for clinical trial 
number seems to be the cancer incidence rate. Five-year sur-
vival rates help to better explain clinical trial count, with more 
trials for cancers with shorter survival. Cancer prevalence in 
the USA is only a weak predictor of research output. Cancer 
publication count is strongly positively correlated with clinical 
trial count. It, too, depends on cancer incidence and five-
year survival rate. Marginally more than half of glioblastoma 
treatment options have had glioblastoma-targeted scientific 
publications before having a clinical trial conducted. This 
observation remains constant over time.
The number of new glioblastoma treatment options as well 
as new mechanisms of action is rapidly growing each year. 
However, the specificity of their publications for glioblastoma is 
low, with no clear trend of increase over time. The results reveal 
also that interventions are tested in glioblastoma, on average, 
10 years after they were first published on other neoplasms. 
More than half of clinical trial interventions have only been 
tested in single trials. The vast majority was tested in earlier 
phase clinical trials, which is consistent with what Cihoric et al. 
observed in their 2017 review [34]. However, there seems to be 
a trend for a moderate increase in the number of glioblastoma 
treatment options studied in phase IV clinical trials, and no 
clear negative trend for phase III was demonstrated.
Searching ClinicalTrials.gov website is a faster, more con-
venient, and reliable way of gathering a comprehensive list of 
glioblastoma treatment options than analysing publications 
on PubMed. Given the strong correlation between clinical 
trials and publications for glioblastoma and other cancers, 
the same premise might hold true for the latter. However, data 
on glioblastoma clinical trials’ interventions could be better 
organised on ClinicalTrials.gov. Categorisation into inter-
vention types (‘drug’, ‘device’, etc.) in its current form cannot 
be used to reliably filter interventions. Separating treatment 
from dosage and maintaining a list of unique treatments would 
prevent categorising the same treatment as different entities. 
There have been successful attempts to overcome this issue by 
privately-run databases such as Springer’s AdisInsight [41]. 
However, they usually demand a fee and, most importantly, 
still depend on data from ClinicalTrials.gov.
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